

IDL FORMS A JOINT VENTURE WITH CONCILE

IDL Diagnostics, together with its long-term partner concile GmbH, has established a joint venture company. Through this collaboration, IDL Diagnostics' product portfolio will be broadened and marketed to a larger market.

Having signed a letter of intent in May 2025, IDL Diagnostics and the German diagnostics company concile GmbH have created a jointly owned company. The company will drive the global marketing and sales of the companies' products for reader-based rapid tests outside Germany.

The product portfolio is based on the same type of reader that IDL currently uses for UBC Rapid. This means that we will be able to offer a combination of tests using the same reader to our end users. By expanding the product range with products that are well suited for use together with UBC Rapid, we have a more attractive solution for the end user and enable new revenue streams.

"The formation of a joint sales company with concile, where we combine our product portfolios and market knowledge, marks an important milestone for IDL. The joint venture will generate revenue streams from new products while facilitating UBC Rapid's expansion into new markets," says Anders Hultman, CEO of IDL Diagnostics.

The joint venture will participate at WHX Labs in Dubai from 10–13 February, where representatives from both Sweden and Germany will promote the company's rapid tests and how these can be used to deliver accurate and fast results.

Formally, the agreement is entered into between concile GmbH's parent company, MBC Holding GmbH, and IDL Diagnostics' subsidiary IDL Biotech AB.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com

This information is information that IDL Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-05 14:01 CET.

Attachments

[IDL forms a joint venture with concile](#)